You are here: Home: Audio Program Guide: PCU 2 | 2007 Audio: PCU 2 | 2007
 
 

Go to Case 1 (from Dr Keane’s practice)
Go to Case 2 (from Dr Gomella’s practice)
Go to Case 3 (from Dr Zelefsky’s practice)
Go to Case 4 (from Dr Moul’s practice)
Go to Case 5 (from Dr Crawford’s practice)
Go to Case 6 (from Dr Taplin’s practice)
Go to Case 7 (from Dr Freedland’s practice)
Go to Case 8 (from Dr Roach’s practice)
Go to Case 9 (from Dr Moul’s practice)
Go to Case 10 (from Dr Freedland’s practice)
Go to Case 11 (from Dr Roach’s practice)
 
 

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Keane, MD Case 1 (from the practice of Thomas E Keane, MBBCh):
A 37-year-old man who presented with a PSA level of 37 ng/mL, a palpable prostate nodule and Gleason 4 + 3 prostate cancer.
  
  Click here to download the entire segment  
Track 1 A 37-year-old man with Gleason 4 + 3 prostate cancer and a PSA of 37 ng/mL
Track 2 CALGB-90203: Neoadjuvant docetaxel and androgen deprivation prior to prostatectomy
Track 3 Modalities for staging prostate cancer prior to surgery
Track 4 Counseling patients about realistic treatment goals: Long-term disease control versus cure
Track 5 Surgery versus radiation therapy as local treatment for high-risk prostate cancer
Track 6 Interdisciplinary collaboration in the treatment of early prostate cancer

Track 7 Multimodality therapy for a younger patient with high-risk prostate cancer
     
Gomella, MD Case 2 (from the practice of Leonard G Gomella, MD):
A 50-year-old man who presented with an initial-screening PSA level of 47 ng/mL, a 120-g prostate and Gleason 8 and 9 prostate cancer with possible rectal wall invasion
  
  Click here to download the entire segment  
Track 1 A 50-year-old man with Gleason 8/9 locally advanced prostate cancer (LAPC) with rectal wall invasion
Track 2 The Internet as a resource for prostate cancer patients
Track 3 Treatment approach for patients with high-grade LAPC
Track 4 Tumor response to neoadjuvant docetaxel with combined androgen blockade (CAB)
Track 5 Clinical depression during hormonal therapy for prostate cancer
Track 6 Testosterone supplementation for patients with previously treated prostate cancer

     
Zelefsky, MD Case 3 (from the practice Michael J Zelefsky, MD):
A 55-year-old man who presented three years ago with T3, Gleason 9 locally advanced prostate cancer with seminal vesicle involvement who refused surgery and hormone therapy
  
  Click here to download the entire segment  
Track 1 A 55-year-old man with T3, Gleason 9 LAPC with seminal vesicle involvement who refused surgery and
hormone therapy
Track 2 Brachytherapy in combination with intensity-modulated external beam radiation therapy for LAPC
     
Moul, MD Case 4 (from the practice of Judd W Moul, MD):
A 60-year-old man diagnosed with Gleason 6 and 7 prostate cancer and metastases in the ribs and spine
  
  Click here to download the entire segment  
Track 1 A 60-year-old man presenting with de novo metastatic prostate cancer
Track 2 Provision of hope for patients with metastatic disease
Track 3 CAB with zoledronic acid for a patient with symptomatic bone metastases
Track 4 Recent ASCO guidelines regarding the use of CAB
Track 5 Factors influencing physicians’ perceptions of risk-benefit tradeoff for CAB
Track 6 Treatment of progression during CAB

Track 7 Docetaxel/prednisone for hormone-refractory metastatic prostate cancer
Track 8 Treatment of progression during CAB

     
Crawford, MD Case 5 (from the practice of E David Crawford, MD):
A 46-year-old man with a strong family history of prostate cancer and an initial PSA level of 15 ng/mL. Ten out of 12 biopsies were positive for Gleason 7 prostate cancer. Radical prostatectomy revealed extensive disease, positive margins and minimal seminal vesicle invasion
  
  Click here to download the entire segment  
Track 1 A 46-year-old man with a strong family history of prostate cancer, a screening PSA of 15 ng/mL,
Gleason 7 disease, seminal vesicle involvement and positive margins postprostatectomy
Track 2 Staging approaches in prostate cancer
Track 3 Treatment options for patients at high risk of recurrence following prostatectomy
Track 4 Immediate versus salvage radiation therapy for patients with high-risk disease postprostatectomy
Track 5 Adjuvant chemotherapy for patients at high risk of relapse postprostatectomy

     
Taplin, MD Case 6 (from the practice of Mary-Ellen Taplin, MD):
A 50-year-old man who underwent robotic prostatectomy revealing Gleason 8 prostate cancer with seminal vesicle involvement but negative margins
  
  Click here to download the entire segment  
Track 1 A 50-year-old man with Gleason 8 prostate cancer with seminal vesicle involvement and negative margins postprostatectomy
Track 2 Robotic prostatectomy and lymph node dissection
Track 3 Treatment options for a patient with high-risk disease who refuses hormonal therapy
Track 4 Bicalutamide monotherapy as adjuvant therapy
     
Freeland, MD Case 7 (from the practice of Stephen J Freedland, MD):
A 63-year-old man with Gleason 4 + 3, node-positive prostate cancer and a PSA of 160 ng/mL
  
  Click here to download the entire segment  
Track 1 A 63-year-old man with Gleason 4 + 3, node-positive prostate cancer and a PSA of 160 ng/mL
Track 2 Duration of adjuvant antiandrogen therapy
Track 3 Rationale for radiation therapy in node-positive prostate cancer
Track 4 Testosterone levels after cessation of androgen deprivation therapy
Track 5 Combined radiation therapy and hormonal therapy for patients with node-positive prostate cancer

     
Roach, MD Case 8 (from the practice of Mack Roach III, MD):
A patient with positive nodes postprostatectomy treated with hormonal therapy and radiation therapy
  
  Click here to download the entire segment  
Track 1 A patient with positive nodes postprostatectomy treated with hormonal therapy and radiation therapy
Track 2 Immediate versus delayed hormone therapy in node-positive prostate cancer
     
Moul, MD Case 9 (from the practice of Dr Moul):
A 67-year-old man who underwent radical prostatectomy for Gleason 5 + 3 prostate cancer with extracapsular extension and negative margins
  
  Click here to download the entire segment  
Track 1 A 67-year-old man with Gleason 5 + 3 prostate cancer with bilateral extracapsular extension, perineural invasion and negative margins postprostatectomy
Track 2 Primary treatment options for LAPC
Track 3 SWOG-S9921: Adjuvant androgen deprivation with or without mitoxantrone and prednisone postprostatectomy for patients with high-risk disease
Track 4 Management of hot flashes secondary to hormone therapy
Track 5 Risk of leukemia secondary to anthracycline-based chemotherapy
Track 6 Ongoing clinical trials with docetaxel in the adjuvant setting

Track 7 Predicting prognosis of a high-risk patient treated with hormonal therapy and docetaxel
Track 8 Utility of testosterone levels in patients with continued androgen suppression and PSA progression
     
Freeland, MD Case 10 (from the practice of Dr Freedland):
A 75-year-old man with PSA-only progression after radical prostatectomy with a doubling time of two years
  
  Click here to download the entire segment  
Track 1 A 75-year-old man with PSA-only progression after radical prostatectomy with a doubling time of two years
Track 2 Combined radiation therapy and hormone therapy postprostatectomy in patients with rising PSA levels
Track 3 Use of new technologies to improve the accuracy of radiation therapy in prostate cancer
Track 4 Phoenix definition for biochemical failure after the treatment of prostate cancer
     
Roach, MD Case 11 (from the practice of Dr Roach):
A man in his early fifties with Gleason 6, node-negative prostate cancer and significant pretreatment PSA doubling time
  
  Click here to download the entire segment  
Track 1 A man in his early fifties with Gleason 6, node-negative prostate cancer and significant pretreatment PSA
doubling time
Track 2 Treatment options for a younger man with low-grade prostate cancer and rapid preoperative PSA doubling time
Track 3 Importance of diet and exercise for cancer patients